Vaccine related ME/CFS demonstrating aluminium overload

Discussion in 'Fibromyalgia Main Forum' started by tansy, Nov 19, 2008.

  1. tansy

    tansy New Member


    Vaccine Related Chronic Fatigue Syndrome In An Individual
    Demonstrating Aluminium Overload

    A team of scientists have investigated a case of vaccine-associated
    chronic fatigue syndrome (CFS) and macrophagic myofasciitis in an
    individual demonstrating aluminium overload.

    This is the first report linking aluminium overload with either of
    the two conditions and the possibility is considered that the
    coincident aluminium overload contributed significantly to the
    severity of these conditions in a patient.

    The team, led by Dr Chris Exley, of the Birchall Centre at Keele
    University in Staffordshire, UK, has found a possible mechanism
    whereby vaccination involving aluminium-containing adjuvants could
    trigger the cascade of immunological events that are associated with
    autoimmune conditions, including chronic fatigue syndrome and
    macrophagic myofasciitis.

    The CFS in a 43-year-old man, with no history of previous illness,
    followed a course of five vaccinations, each of which included an
    aluminium-based adjuvant. The latter are extremely effective
    immunogens in their own right and so improve the immune response to
    whichever antigen is administered in their presence. While the course
    of vaccinations was cited by an industrial injuries tribunal as the
    cause of the CFS in the individual, it was not likely to be a cause
    of the elevated body burden of aluminium. The latter was probably
    ongoing at the time when the vaccinations were administered and it is
    proposed that the cause of the CFS in this individual was a
    heightened immune response, initially to the aluminium in each of the
    adjuvants and thereafter spreading to other significant body stores
    of aluminium.

    The result was a severe and ongoing immune response to elevated body
    stores of aluminium, which was initiated by a course of five
    aluminium adjuvant-based vaccinations within a short period of time.
    There are strong precedents for delayed hypersensitivity to aluminium
    in children receiving vaccinations which include aluminium-based
    adjuvants, with as many as 1% of recipients showing such a response.

    While the use of aluminium-based adjuvants may be safe, it is also
    possible that for a significant number of individuals they may
    represent a significant health risk, such as was found in this case.
    With this in mind the ongoing programme of mass vaccination of young
    women in the UK against the human papilloma virus (HPV) with a
    vaccine which uses an aluminium based adjuvant may not be without
    similar risks.

    Recent press coverage of myalgic encephalomyelitis (ME) or chronic
    fatigue syndrome has highlighted the potentially debilitating nature
    of this disease and related conditions. The cause of CFS is unknown.